IRD OPGX-BEST1 gene therapy meets FDA-aligned microperimetry endpoint
IRD says Phase 1/2 low-dose OPGX-BEST1 in BVMD and ARB showed strong safety and encouraging efficacy, with 75% of evaluable participants meeting an FDA-aligned microperimetry endpoint and noted structural and functional improvements.